close
February 04 ,  2021

SOFIVA Genomics’ Monthly Consolidated Sales Revenue Increased by 7.88% in Dec

SOFIVA Genomics, a leading brand in genetic testing, has revealed its outstanding sales of cancer genetic testing products since late 2020, which contributed to a boost in the company’s year-end revenue momentum. In last December, SOFIVA Genomics’ monthly consolidated sales revenue growth reached 7.88%, a 2.42% increase compared to numbers from the previous year.

Precision Medicine Trends Motivate Growth in Genetic Testing

Five-fold Growth in the Average Monthly Sales of Cancer Genetic Testing Products

As the government and public increasingly value the application of precision medicine in cancer treatment, cancer genetic testing products have observed the greatest growth momentum among SOFIVA Genomics’ product sales and layout in 2020. Over the past two years, these products have exhibited a 250% growth. Coupled with precision medicine and testing trends, the BRCA1/2 genetic testing product achieved a 5-fold growth in last December, when compared with the previous 11 months.

SOFIVA General Manager Chia-Cheng Hung explained, “The sales momentum we have seen in the BRCA1/2 gene testing product is linked to precision medicine. Olaparib, a drug used to treat cancer patients with the BRCA1 and BRCA2 mutations, was recently included in National Health Insurance last November, which has fueled market demand for genetic testing. SOFIVA’s non-invasive testing method allows for physicians to provide more diverse options to patients in different stages of treatment, which then further creates sales momentum.”

BRCA1 and BRCA2 mutations increase the risk of certain types of cancer, including breast cancer, ovarian cancer, endometrial cancer, and prostate cancer. Other than its application in treatment for cancer patients, this genetic test sheds light on what preventative medical measures need to be taken for those with a family history of these types of cancer.

SOFIVA Invests in Dianthus Medical Group and Exhibits Stable Expansion

In 2020, SOFIVA’s Revenue Grew by a Sweeping 20%

As a result of cross investment in Dianthus Medical Group, SOFIVA’s affiliated revenue grew by 20% in 2020 when compared with the previous year. General Manager Chia-Cheng Hung adds, “In addition to collaborating with Dianthus Medical Group to rollout testing products and services, we have also invested in Dianthus Medical Group, which has brought about stable revenue for SOFIVA. Furthermore, by comprehensively integrating our industry chain, we are able to better identify industry demands and development trends. On top of looking forward to an increased revenue generated by Dianthus Medical Group’s stable growth, we are also focused on proactively exploring the possibilities of collaborating with major domestic medical centers and mid-to-small-sized hospitals in 2020.”